MicroRNA-145 Impedes Thrombus Formation via Targeting Tissue Factor in Venous Thrombosis

EBioMedicine. 2017 Dec:26:175-186. doi: 10.1016/j.ebiom.2017.11.022. Epub 2017 Nov 23.

Abstract

Venous thromboembolism (VTE), the third leading cardiovascular complication, requires more understanding at molecular levels. Here, we have identified miR-145 as a key molecule for regulating thrombus formation in venous thrombosis (VT) employing network based bioinformatics approach and in vivo experiments. Levels of miR-145 showed an inverse correlation with thrombus load determined by coagulation variables. MiRNA target prediction tools and in vitro study identified tissue factor (TF) as a target gene for miR-145. The restoration of miR-145 levels in thrombotic animals via in vivo miR-145 mimic delivery resulted in decreased TF level and activity, accompanied by reduced thrombogenesis. MiR-145 levels were also reduced in VT patients and correlated with increased TF levels in patients, thereby, confirming our preclinical findings. Our study identifies a previously undescribed role of miRNA in VT by regulating TF expression. Therefore, restoration of miR-145 levels may serve as a promising therapeutic strategy for management of VT.

Keywords: Antithrombotic therapy; Coagulation; Tissue factor; Venous thrombosis; miRNA.

MeSH terms

  • Animals
  • Blood Coagulation / genetics
  • Disease Models, Animal
  • Gene Expression Regulation / genetics
  • Humans
  • MicroRNAs / genetics*
  • Rats
  • Thromboplastin / genetics*
  • Thrombosis / genetics*
  • Thrombosis / physiopathology
  • Venous Thromboembolism / genetics
  • Venous Thromboembolism / pathology
  • Venous Thrombosis / genetics*
  • Venous Thrombosis / physiopathology

Substances

  • MIRN145 microRNA, human
  • MicroRNAs
  • Thromboplastin